Management of adverse events during cyclin-dependent kinase 4/6 (CDK4/6) inhibitor-based treatment in breast cancer

Cyclin-dependent kinase (CDK) 4/6 inhibitors have shown great results in numerous clinical trials and have improved the clinical outcome for patients with hormone-receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer significantly. To date, three CDK4/6 inhibito...

Descripción completa

Detalles Bibliográficos
Autores principales: Thill, Marc, Schmidt, Marcus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6122233/
https://www.ncbi.nlm.nih.gov/pubmed/30202447
http://dx.doi.org/10.1177/1758835918793326

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6122233/
https://www.ncbi.nlm.nih.gov/pubmed/30202447
http://dx.doi.org/10.1177/1758835918793326

Ejemplares similares